ea0090p402 | Pituitary and Neuroendocrinology | ECE2023
Brue Thierry
, Fleseriu Maria
, Barkan Ariel
, Duquesne Edouard
, Houchard Aude
, del Pilar Schneider Maria
, Ribeiro-Oliveira Antonio
, Melmed Shlomo K.
Background: Medical treatment for acromegaly (characterized by excess growth hormone [GH] production) includes somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and GH receptor antagonists (GHRAs). However, recent real-world United States (US) treatment evaluations are few. We present treatment patterns for patients receiving medications for acromegaly (1/1/201031/7/2022).Methods: De-identified data were extracted from MarketScan&...